Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed...
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
About this item
Full title
Author / Creator
Kroschinsky, Frank , Middeke, Jan Moritz , Janz, Martin , Lenz, Georg , Witzens-Harig, Mathias , Bouabdallah, Reda , La Rosée, Paul , Viardot, Andreas , Salles, Gilles , Kim, Seok Jin , Kim, Tae Min , Ottmann, Oliver , Chromik, Joerg , Quinson, Anne-Marie , von Wangenheim, Ute , Burkard, Ute , Berk, Andreas and Schmitz, Norbert
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Alternative Titles
Full title
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8025269
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8025269
Other Identifiers
ISSN
0167-6997
E-ISSN
1573-0646
DOI
10.1007/s10637-020-00949-8
